,,trastuzumab deruxtecan
astrazeneca,daiichi sankyo
['destiny,breast,4', 'breast', 'destiny-breast04', 'enhertu', 'astrazeneca', 'daiichi']
the destiny-breast04 trial looks predestined to launch enhertu into the her2-low unresectable or metastatic breast cancer setting. how practice-changing will this data from astrazeneca and daiichisankyo be? #asco22 #oncology #breastcancer 
Bringing remarkable clarity to life sciences’ and healthcare's most important decisions.